284: Detecting 1 in 100,000 Cells: DNA Barcoding for Smarter Clone Selection with Kent Rapp - Part 2

“Does DNA barcoding actually work?” It's the first question Kent Rapp hears from prospective customers when he pitches Biolinco's DNA barcoding platform. By his own admission, the technology can sound too good to be true.

In Part 2 of this conversation, Kent rejoins the Smart Biotech Scientist Podcast to address that skepticism head-on, unpack how subclone variability and bispecific antibody purity concerns shape customer trust, and share what it actually took to move Biolinco from a Johns Hopkins postdoc project to a company with its first paying customer.

In this episode:

• Common pushbacks and questions from industry regarding new cell line development technologies (03:18)
• Practical advice for resource-constrained startups developing cell lines, emphasizing efficiency and data quality over brute force automation (08:42)
• The role and value of DNA barcoding in screening and developing robust cell lines for therapeutics (08:56)
• Lessons learned from translating scientific innovation into a commercial product, including securing early support and customer trust (10:27)
• Insights on adapting messaging, leveraging feedback, and understanding market needs as part of the entrepreneurial process (13:52)
• Key differences between academic research and industry requirements for reliable, repeatable biotech tools (15:26)
• Kent’s most important takeaway for successful cell line development: focus on collecting the right data at the right scale for informed decisions (17:14)

Smart insight: Translating innovations from academia to industry brings a new wave of challenges. Kent describes the “valley of death” separating a publishable prototype from a reliable, commercial-grade product. Academic success is often tied to novelty, publications, and grants, while industry demands repeatability, robustness, and consistent performance across labs and operators. Securing early champions and funding, iterating based on tough industry feedback, and building trust with initial partners all require resilience, and a willingness to pivot as needed. Feedback, even when harsh, becomes a “gift” that helps refine the product and business model. The secret is not a single breakthrough, but adaptability and relentless customer focus.

If this got you rethinking how you screen clones, you'll want these next. We've tackled cell line development, high-throughput screening, and the art of spotting manufacturable candidates early from a few different directions — here are four worth queuing up.

• Episodes 117 - 118 : Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough
• Episodes 09 - 10: Revolutionizing Cell-Line Development: Unleashing the Power of Nanopens and Microenvironments with Tanner Nevill
• Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
• Episodes 115 - 116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti

Connect with Kent Rapp:
LinkedIn: www.linkedin.com/in/kent-rapp
Biolinco website: www.biolinco.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show